 Study NCT00055497 was designed to evaluate the efficacy and safety of adalimumab in the maintenance of clinical remission in patients with Crohns disease CD. The study consisted of 2 phases: 1. the first year phase lasting until Week 56 and consisting of a randomized, double-blind DB, placebo-controlled portion NCT00055497 and of a concomitant open label OL portion, and 2. a long-term extension phase NCT01070303 that lasted 264 additional weeks Week 56 to Week 320. 